Insider trading · Q3 2026 · CIK 1889109

Belite Bio, Inc (BLTE) insider trading.

In Q3 2026, insiders at Belite Bio, Inc reported 42 non-derivative transactions on 4 Forms 3, 4 and 5: 0 open-market purchases and 42 sales worth $32.0M.

Transactions
42
Purchases (P)
0
Sales (S)
42
Net shares, P minus S
-168,562
Insiders
2
Last filed
2026-09-09

Insiders

InsiderRelationshipTransactionsBuysSales
Chuang Hao-YuanDirector, Officer · Chief Financial Officer21021
Lin Yu-HsinDirector, Officer · Chief Executive Officer21021

Transactions

42 non-derivative rows, newest transaction first. Shares and prices as filed.
DateInsiderCodeSharesPriceOwned afterFiling
2026-09-08Chuang Hao-YuanS (D)2,562$198.0526,038Form 4
2026-09-08Chuang Hao-YuanS (D)2,200$194.2841,800Form 4
2026-09-08Chuang Hao-YuanS (D)4,120$195.637,680Form 4
2026-09-08Chuang Hao-YuanS (D)4,475$196.4733,205Form 4
2026-09-08Chuang Hao-YuanS (D)4,605$197.2328,600Form 4
2026-09-08Lin Yu-HsinS (D)6,058$196.5481,586Form 4
2026-09-08Lin Yu-HsinS (D)8,752$197.3672,834Form 4
2026-09-08Lin Yu-HsinS (D)2,700$198.0970,134Form 4
2026-09-08Lin Yu-HsinS (D)2,400$194.3393,734Form 4
2026-09-08Lin Yu-HsinS (D)6,090$195.6287,644Form 4
2026-09-04Chuang Hao-YuanS (D)1,633$180.1691,800Form 4
2026-09-04Chuang Hao-YuanS (D)2,000$182.4987,800Form 4
2026-09-04Chuang Hao-YuanS (D)3,759$183.2784,041Form 4
2026-09-04Chuang Hao-YuanS (D)3,569$184.5780,472Form 4
2026-09-04Chuang Hao-YuanS (D)3,872$185.2876,600Form 4
2026-09-04Chuang Hao-YuanS (D)4,600$186.3572,000Form 4
2026-09-04Chuang Hao-YuanS (D)3,900$187.1668,100Form 4
2026-09-04Chuang Hao-YuanS (D)1,900$188.5966,200Form 4
2026-09-04Chuang Hao-YuanS (D)6,200$189.2260,000Form 4
2026-09-04Chuang Hao-YuanS (D)1,800$190.6358,200Form 4
2026-09-04Chuang Hao-YuanS (D)6,200$191.0952,000Form 4
2026-09-04Chuang Hao-YuanS (D)3,398$192.448,602Form 4
2026-09-04Chuang Hao-YuanS (D)4,602$193.1244,000Form 4
2026-09-04Chuang Hao-YuanS (D)2,000$181.0589,800Form 4
2026-09-04Lin Yu-HsinS (D)8,111$193.1396,134Form 4
2026-09-04Lin Yu-HsinS (D)2,635$180.29167,934Form 4
2026-09-04Lin Yu-HsinS (D)2,587$181.24165,347Form 4
2026-09-04Lin Yu-HsinS (D)3,413$182.5161,934Form 4
2026-09-04Lin Yu-HsinS (D)4,955$183.3156,979Form 4
2026-09-04Lin Yu-HsinS (D)6,252$184.52150,727Form 4
2026-09-04Lin Yu-HsinS (D)4,593$185.34146,134Form 4
2026-09-04Lin Yu-HsinS (D)7,800$186.32138,334Form 4
2026-09-04Lin Yu-HsinS (D)6,200$187.25132,134Form 4
2026-09-04Lin Yu-HsinS (D)3,045$188.26129,089Form 4
2026-09-04Lin Yu-HsinS (D)8,955$189.34120,134Form 4
2026-09-04Lin Yu-HsinS (D)600$190.39119,534Form 4
2026-09-04Lin Yu-HsinS (D)11,080$191.15108,454Form 4
2026-09-04Lin Yu-HsinS (D)4,209$192.54104,245Form 4
2026-08-12Lin Yu-HsinS (D)223$180.57170,569Form 4
2026-08-12Lin Yu-HsinS (D)142$180170,792Form 4
2026-08-12Chuang Hao-YuanS (D)144$18093,656Form 4
2026-08-12Chuang Hao-YuanS (D)223$180.5793,433Form 4

Transaction codes in this quarter

Get BLTE insider transactions through the API

Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1889109&limit=100" \
  -H "Authorization: Bearer $SEC_API_KEY"

Insider trading API guide · BLTE company page · Belite Bio, Inc on SEC.gov

Questions

Are insiders buying or selling Belite Bio, Inc (BLTE)?

In Q3 2026, insiders at Belite Bio, Inc reported 42 non-derivative transactions on 4 Forms 3, 4 and 5: 0 open-market purchases and 42 sales worth $32.0M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.

Where do these Belite Bio, Inc insider trades come from?

From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.

Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.

Plain-text version for agents and LLMs: /insider-trading/blte.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.